INmune Bio Shares Drop as Alzheimer's Treatment Study Remains on Hold
By Dean Seal
Shares of INmune Bio fell after the company said the study for its Alzheimer's disease treatment would remain on full clinical hold.
The stock was down 14% at $9.86 in premarket trading. Shares had gained 82% year-to-date when the market closed Monday.
The Boca Raton, Fla.-based immunology company said after the bell Monday that the U.S. Food and Drug Administration had requested additional information on the long-term potency of the treatment.
INmune Bio said it would provide clarification to the FDA in response before the end of the year, which it believes will resolve remaining questions. The FDA is the only regulatory agency to put the trial on hold, and patient recruitment projections don't rely on any sites in the U.S., the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 19, 2023 06:47 ET (11:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month